|
GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for $1 billion upfront, as well as up to $400 million in certain success-based milestone payments. The Brentford, West London-based pharmaceutical company said the acquisition will help boost its respiratory pipeline, as it will gain access to Aiolos’ anti-thymic stromal lymphopoietin monoclonal antibody, AIO-001. According to GSK, AIO-001 is currently ready to enter phase 2 clinical development for the treatment of adult patients with asthma, with the potential for additional indications including chronic rhinosinusitis with nasal polyps. GSK Chief Scientific Director Tony Wood said: ‘Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.’ Shares in GSK rose 0.1% to 1,550.40 pence each in London on Tuesday morning. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
